Replicative oncolytic herpes simplex viruses in combination cancer therapies

Current Gene Therapy

Volumn 4, Issue 1, 2004, Pages 41-51

  Post, Dawn E ^a   Fulci, Giulia ^b   Chiocca, E Antonio ^b   Van Meir, Erwin G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Gene therapy; Herpes simplex virus 1; Oncolytic virus; Radiation; Tumors

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B1; CYTOSINE DEAMINASE; DOXORUBICIN; FLUCYTOSINE; GANCICLOVIR; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; IFOSFAMIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; METHOTREXATE; MITOMYCIN C; ONCOLYTIC VIRUS; THYMIDINE KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SPECIFICITY; CLINICAL TRIAL; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; GENE THERAPY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; LIFE CYCLE; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS REPLICATION;

CHEMOTHERAPY, ADJUVANT; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MUTATION; NEOPLASMS; RADIOTHERAPY, ADJUVANT; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 2342641762     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523044577988     Document Type: Review

References (80)

1. Adachi, Y., Reynolds, P. N., Yamamoto, M., Wang, M., Takayama, K., Matsubara, S., Muramatsu, T. and Curiel, D. T. (2001) A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res., 61: 7882-7888.
2. Advani, S. J., Chung, S. M., Yan, S. Y., Gillespie, G. Y., Markert, J. M., Whitley, R. J., Roizman, B. and Weichselbaum, R. R. (1999) Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res., 59: 2055-2058.
3. Advani, S. J., Sibley, G. S., Song, P. Y., Hallahan, D. E., Kataoka, Y., Roizman, B. and Weichselbaum, R. R. (1998) Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther., 5: 160-165.
4. Aghi, M., Chou, T. C., Suling, K., Breakefield, X. O. and Chiocca, E. A. (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res., 59: 3861-3865.
5. Aghi, M., Hochberg, F. and Breakefield, X. O. (2000) Prodrug activation enzymes in cancer gene therapy. J. Gene. Med., 2: 148-164.
6. Anderson, D. B., Laquerre, S., Ghosh, K., Ghosh, H. P., Goins, W. F., Cohen, J. B. and Glorioso, J. C. (2000) Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J. Virol., 74: 2481-2487.
7. Andreansky, S., He, B., van Cott, J., McGhee, J., Markert, J. M., Gillespie, G. Y., Roizman, B. and Whitley, R. J. (1998) Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther., 5: 121-130.
8. Bennett, J. J., Malhotra, S., Wong, R. J., Delman, K., Zager, J., St-Louis, M., Johnson, P. and Fong, Y. (2001) Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann. Surg., 233: 819-826.
9. Blank, S. V., Rubin, S. C., Coukos, G., Amin, K. M., Albelda, S. M. and Molnar-Kimber, K. L. (2002) Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum. Gene Ther., 13: 627-639.
10. Boviatsis, E. J., Park, J. S., Sena-Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M. X., Breakefield, X. O. and Chiocca, E. A. (1994) Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res., 54: 5745-5751.
11. Bradley, J. D., Kataoka, Y., Advani, S., Chung, S. M., Arani, R. B., Gillespie, G. Y., Whitley, R. J., Markert, J. M., Roizman, B. and Weichselbaum, R. R. (1999) Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res., 5: 1517-1522.
12. Carroll, N. M., Chase, M., Chiocca, E. A. and Tanabe, K. K. (1997) The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J. Surg. Res., 69: 413-417.
13. Chahlavi, A., Todo, T., Martuza, R. L. and Rabkin, S. D. (1999) Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia, 1: 162-169.
14. Chase, M., Chung, R. Y. and Chiocca, E. A. (1998) An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol., 16: 444-448.
15. Chen, Y., DeWeese, T., Dilley, J., Zhang, Y., Li, Y., Ramesh, N., Lee, J., Pennathur-Das, R., Radzyminski, J., Wypych, J., Brignetti, D., Scott, S., Stephens, J., Karpf, D. B., Henderson, D. R. and Yu, D. C. (2001) CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res., 61: 5453-5460.
16. Chiocca, E. A. (2002) Oncolytic viruses. Nature Reviews Cancer, 2: 938-951.
17. Chou, J., Kern, E. R., Whitley, R. J. and Roizman, B. (1990) Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science, 250: 1262-1266.
18. Chung, R. Y., Saeki, Y. and Chiocca, E. A. (1999) B-myb promoter retargeting of herpes simplex virus gamma34.5 gene- mediated virulence toward tumor and cycling cells. J. Virol., 73: 7556-7564.
19. Chung, S. M., Advani, S. J., Bradley, J. D., Kataoka, Y., Vashistha, K., Yan, S. Y., Markert, J. M., Gillespie, G. Y., Whitley, R. J., Roizman, B. and Weichselbaum, R. R. (2002) The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther., 9: 75-80.
20. Coukos, G., Makrigiannakis, A., Kang, E. H., Caparelli, D., Benjamin, I., Kaiser, L. R., Rubin, S. C., Albelda, S. M. and Molnar-Kimber, K. L. (1999) Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res., 5: 1523-1537.
21. Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R. and Gillespie, G. Y. (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res., 5: 985-990.
22. DeLuca, N. A., McCarthy, A. M. and Schaffer, P. A. (1985) Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol., 56: 558-570.
23. Farassati, F., Yang, A. D. and Lee, P. W. (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell. Biol., 3: 745-750.
24. Fuerer, C. and Iggo, R. (2002) Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther., 9: 270-281.
25. Fulci, G. and Chiocca, E. A. (2002) Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Frontiers in Bioscience, 8: e346-360.
26. Geraghty, R. J., Krummenacher, C., Cohen, G. H., Eisenberg, R. J. and Spear, P. G. (1998) Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science, 280: 1618-1620.
27. Hernandez-Alcoceba, R., Pihalja, M., Qian, D. and Clarke, M. F. (2002) New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther., 13: 1737-1750.
28. Jorgensen, T. J., Katz, S., Wittmack, E. K., Varghese, S., Todo, T., Rabkin, S. D. and Martuza, R. L. (2001) Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia, 3: 451-456.
29. Kooby, D. A., Carew, J. F., Halterman, M. W., Mack, J. E., Bertino, J. R., Blumgart, L. H., Federoff, H. J. and Fong, Y. (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J., 13: 1325-1334.
30. Lambright, E. S., Amin, K., Wiewrodt, R., Force, S. D., Lanuti, M., Propert, K. J., Litzky, L., Kaiser, L. R. and Albelda, S. M. (2001) Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther., 8: 946-953.
31. Laquerre, S. anderson, D. B., Stolz, D. B. and Glorioso, J. C. (1998a) Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells. J. Virol., 72: 9683-9697.
32. Laquerre, S., Argnani, R. anderson, D. B., Zucchini, S., Manservigi, R. and Glorioso, J. C. (1998b) Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration and cell-to-cell spread. J. Virol., 72: 6119-6130.
33. Liu, B. L., Robinson, M., Han, Z. Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., Love, C. A. and Coffin, R. S. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating and anti-tumour properties. Gene Ther., 10: 292-303.
34. MacKie, R. M., Stewart, B. and Brown, S. M. (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 357: 525-526.
35. MacLean, A. R., ul-Fareed, M., Robertson, L., Harland, J. and Brown, S. M. (1991) Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol., 72: 631-639.
36. Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tomatore, C., Tufaro, F. and Martuza, R. L. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther., 7: 867-874.
37. Markert, J. M., Parker, J. N., Gillespie, G. Y. and Whitley, R. J. (2001) Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes, 8: 17-22.
38. Marples, B., Scott, S. D., Hendry, J. H., Embleton, M. J., Lashford, L. S. and Margison, G. P. (2000) Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther., 7: 511-517.
39. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L. and Coen, D. M. (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252: 854-856.
40. Meignier, B., Longnecker, R. and Roizman, B. (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis., 158: 602-614.
41. Meignier, B., Martin, B., Whitley, R. J. and Roizman, B. (1990) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis., 162: 313-321.
42. Mineta, T., Rabkin, S. D. and Martuza, R. L. (1994) Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res., 54: 3963-3966.
43. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. and Martuza, R. L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943.
44. Mintz, A., Gibo, D. M., Slagle-Webb, B., Christensen, N. D. and Debinski, W. (2002) IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia, 4: 388-399.
45. Miyatake, S., Iyer, A., Martuza, R. L. and Rabkin, S. D. (1997) Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol., 71: 5124-5132.
46. Miyatake, S. I., Tani, S., Feigenbaum, F., Sundaresan, P., Toda, H., Narumi, O., Kikuchi, H., Hashimoto, N., Hangai, M., Martuza, R. L. and Rabkin, S. D. (1999) Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther., 6: 564-572.
47. Montgomery, R. I., Warner, M. S., Lum, B. J. and Spear, P. G. (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell, 87: 427-436.
48. Mullen, J. T., Kasuya, H., Yoon, S. S., Carroll, N. M., Pawlik, T. M., Chandrasekhar, S., Nakamura, H., Donahue, J. M. and Tanabe, K. K. (2002) Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann. Surg., 236: 502-512; discussion 512-503.
49. Nakamura, H., Kasuya, H., Mullen, J. T., Yoon, S. S., Pawlik, T. M., Chandrasekhar, S., Donahue, J. M., Chiocca, E. A., Chung, R. Y. and Tanabe, K. K. (2002) Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest., 109: 871-882.
50. Nakamura, H., Mullen, J. T., Chandrasekhar, S., Pawlik, T. M., Yoon, S. S. and Tanabe, K. K. (2001) Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res., 61: 5447-5452.
51. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S. and Kirn, D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res., 60: 6359-6366.
52. Nettelbeck, D. M., Rivera, A. A., Balague, C., Alemany, R. and Curiel, D. T. (2002) Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res., 62: 4663-4670.
53. Oyama, M., Ohigashi, T., Hoshi, M., Nakashima, J., Tachibana, M., Murai, M., Uyemura, K. and Yazaki, T. (2000) Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum. Gene Ther., 11: 1683-1693.
54. Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J. and Markert, J. M. (2000) Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA, 97: 2208-2213.
55. Pawlik, T. M., Nakamura, H., Mullen, J. T., Kasuya, H., Yoon, S. S., Chandrasekhar, S., Chiocca, E. A. and Tanabe, K. K. (2002) Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer, 95: 1171-1181.
56. Post, D. E. and Van Meir, E. G. (2001) Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther., 8: 1801-1807.
57. Post, D. E. and Van Meir, E. G. (2003) A novel Hypoxia-Inducible Factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene, 22: 2065-2072.
58. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., Mabbs, R. and Brown, M. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 7: 859-866.
59. Randazzo, B. P., Bhat, M. G., Kesari, S., Fraser, N. W. and Brown, S. M. (1997) Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol., 108: 933-937.
60. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W. and Henderson, D. R. (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563.
61. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C. and Kirn, D. H. (2000) In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 60: 1193-1196.
62. Roizman, B. and Sears, A. E. (1996) Herpes simplex viruses and their replication. In: Fields Virology, Eds. B. N. Fields, D. M. Knipe and P. M. Howley, Lippincott-Raven Publishers, Philadelphia, pp. 2231-2295.
63. Sacks, W. R., Greene, C. C., Aschman, D. P. and Schaffer, P. A. (1985) Herpes simplex virus type 1 ICP27 is an essential regulatory protein. J. Virol., 55: 796-805.
64. Saeki, Y., Fraefel, C., Ichikawa, T., Breakefield, X. O. and Chiocca, E. A. (2001) Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther., 3: 591-601.
65. Scott, S. D., Joiner, M. C. and Marples, B. (2002) Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther., 9: 1396-1402.
66. Spear, M. A., Sun, F., Eling, D. J., Gilpin, E., Kipps, T. J., Chiocca, E. A. and Bouvet, M. (2000) Cytotoxicity, apoptosis and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther., 7: 1051-1059.
67. Stanziale, S. F., Petrowsky, H., Joe, J. K., Roberts, G. D., Zager, J. S., Gusani, N. J., Ben-Porat, L., Gonen, M. and Fong, Y. (2002) Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery, 132; 353-359.
68. Toda, M., Rabkin, S. D. and Martuza, R. L. (1998) Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther., 9: 2177-2185.
69. Toyoizumi, T., Mick, R., Abbas, A. E., Kang, E. H., Kaiser, L. R. and Molnar-Kimber, K. L. (1999) Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther., 10: 3013-3029.
70. Varghese, S. and Rabkin, S. D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther., 9: 967-978.
71. Wade-Martins, R., Smith, E. R., Tyminski, E., Chiocca, E. A. and Saeki, Y. (2001) An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol., 19: 1067-1070.
72. Walker, J. R., McGeagh, K. G., Sundaresan, P., Jorgensen, T. J., Rabkin, S. D. and Martuza, R. L. (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther., 10: 2237-2243.
73. Whitley, R. J. (1996) Herpes simplex viruses. In: Fields Virology, Eds. B. N. Fields, D. M. Knipe and P. M. Howley, Lippincott-Raven Publishers, Philadelphia, pp. 2297-2342.
74. Wildner, O. and Morris, J. C. (2000a) The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res., 60: 4167-4174.
75. Wildner, O. and Morris, J. C. (2000b) Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J. Gene. Med., 2: 353-360.
76. Wong, R. J., Kim, S. H., Joe, J. K., Shah, J. P., Johnson, P. A. and Fong, Y. (2001a) Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J. Am. Coll. Surg., 193: 12-21.
77. Wong, R. J., Patel, S. G., Kim, S., DeMatteo, R. P., Malhotra, S., Bennett, J. J., St-Louis, M., Shah, J. P., Johnson, P. A. and Fong, Y. (2001b) Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther., 12: 253-265.
78. Yamamura, H., Hashio, M., Noguchi, M., Sugenoya, Y., Osakada, M., Hirano, N., Sasaki, Y., Yoden, T., Awata, N., Araki, N., Tatsuta, M., Miyatake, S. I. and Takahashi, K. (2001) Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res., 61: 3969-3977.
79. Yoon, S. S., Nakamura, H., Carroll, N. M., Bode, B. P., Chiocca, E. A. and Tanabe, K. K. (2000) An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J., 14: 301-311.
80. Zhou, G., Ye, G. J., Debinski, W. and Roizman, B. (2002) Engineered herpes simplex virus 1 is dependent on IL 13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc. Natl. Acad. Sci. USA, 99: 15124-15129.